Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Open, Multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC Compared to a Booster Dose of Infanrix™ Hexa When Given to 14 Month-old Subjects Primed in Study DTPa-HBV-IPV-097 & Boosted in Study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097

NCT00322335 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00322335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00322335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Open, Multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC Compared to a Booster Dose of Infanrix™ Hexa When Given to 14 Month-old Subjects Primed in Study DTPa-HBV-IPV-097 & Boosted in Study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2006
Completion date
September 30, 2010
Enrollment
230 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilus influenzae type b, neisseria meningitidis